Genefit (GNFTF) 41.3600 $GNFTF
Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:30AM CDT
MNOV: 3.68 (-0.28), GLMD: 10.04 (+0.18), LJPC: 31.43 (+0.94), CNAT: 4.83 (-0.09), GALT: 2.67 (+0.12), RGLS: 10.14 (+0.30), DRRX: 2.48 (+0.15), RPTP: 14.51 (-0.34), GILD: 113.74 (+0.38), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), ICPT: 247.71 (+4.45), VBLT: 6.19 (+0.32), TBRA: 17.24 (+0.72)
Betting On The First NASH Blockbuster Drug: Dump Intercept And Buy Genfit
Logribel Biostocks - at Seeking Alpha - Fri Jun 19, 11:37AM CDT
ICPT: 247.71 (+4.45)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 113.74 (+0.38), GALT: 2.67 (+0.12), FGEN: 22.82 (+0.58), VBAY: (), VBLT: 6.19 (+0.32), CELGZ: 2.15 (+0.14)
The Math Could Get Weird, But Intercept Pharmaceuticals Looks Too Cheap
Stephen Simpson, CFA - at Seeking Alpha - Thu May 21, 7:24AM CDT
GILD: 113.74 (+0.38), CNAT: 4.83 (-0.09), ICPT: 247.71 (+4.45)
Genfit: Why Intercept's NASH Phase 3 Design Is Good News For Genfit
Logribel Biostocks - at Seeking Alpha - Wed May 20, 7:56AM CDT
ICPT: 247.71 (+4.45)
Bluebird Bio, Intercept Pharma Reach Accords on Pivotal Trial Designs
at The Street - Tue May 19, 10:02AM CDT
Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.
BLUE: 159.03 (+0.60), ICPT: 247.71 (+4.45)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 113.74 (+0.38), PFE: 34.36 (+0.50), GALT: 2.67 (+0.12), FGEN: 22.82 (+0.58), CELGZ: 2.15 (+0.14)
Intercept Pharmaceuticals: Serving Unmet Needs With Blockbuster Potential
DoconStocks - at Seeking Alpha - Tue Apr 28, 8:34AM CDT
GILD: 113.74 (+0.38), ICPT: 247.71 (+4.45)
Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
at The Street - Fri Apr 24, 8:12AM CDT
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
ICPT: 247.71 (+4.45)
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Apr 13, 4:18AM CDT
Summary
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 247.71 (+4.45)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 14.51 (-0.34), GILD: 113.74 (+0.38), CNAT: 4.83 (-0.09), ICPT: 247.71 (+4.45)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 247.71 (+4.45)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 247.71 (+4.45), TWTR: 34.91 (+0.55)
Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
at The Street - Fri Mar 27, 8:40AM CDT
The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
ICPT: 247.71 (+4.45)
Intercept up on Genfit's data-messaging presentation of NASH data
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:21PM CDT
ICPT: 247.71 (+4.45)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 99.53 (+1.13), GTXI: 1.37 (+0.01), ESPR: 90.01 (+1.32), ISIS: 53.50 (+0.42), PFE: 34.36 (+0.50), NEOT: 9.91 (+0.68), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin
at The Street - Fri Mar 13, 8:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
AMRN: 2.41 (+0.02), ICPT: 247.71 (+4.45), CUR: 1.69 (-0.01)
Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT
GLMD: 10.04 (+0.18), RPTP: 14.51 (-0.34), GILD: 113.74 (+0.38), LJPC: 31.43 (+0.94), CNAT: 4.83 (-0.09), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), GALT: 2.67 (+0.12), ICPT: 247.71 (+4.45), RGDO: 1.21 (unch)
Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.
at The Street - Wed Mar 11, 8:58AM CDT
It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.
ICPT: 247.71 (+4.45)
Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:30AM CDT
MNOV: 3.68 (-0.28), GLMD: 10.04 (+0.18), LJPC: 31.43 (+0.94), CNAT: 4.83 (-0.09), GALT: 2.67 (+0.12), RGLS: 10.14 (+0.30), DRRX: 2.48 (+0.15), RPTP: 14.51 (-0.34), GILD: 113.74 (+0.38), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), ICPT: 247.71 (+4.45), VBLT: 6.19 (+0.32), TBRA: 17.24 (+0.72)
Betting On The First NASH Blockbuster Drug: Dump Intercept And Buy Genfit
Logribel Biostocks - at Seeking Alpha - Fri Jun 19, 11:37AM CDT
ICPT: 247.71 (+4.45)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 113.74 (+0.38), GALT: 2.67 (+0.12), FGEN: 22.82 (+0.58), VBAY: (), VBLT: 6.19 (+0.32), CELGZ: 2.15 (+0.14)
The Math Could Get Weird, But Intercept Pharmaceuticals Looks Too Cheap
Stephen Simpson, CFA - at Seeking Alpha - Thu May 21, 7:24AM CDT
GILD: 113.74 (+0.38), CNAT: 4.83 (-0.09), ICPT: 247.71 (+4.45)
Genfit: Why Intercept's NASH Phase 3 Design Is Good News For Genfit
Logribel Biostocks - at Seeking Alpha - Wed May 20, 7:56AM CDT
ICPT: 247.71 (+4.45)
Bluebird Bio, Intercept Pharma Reach Accords on Pivotal Trial Designs
at The Street - Tue May 19, 10:02AM CDT
Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.
BLUE: 159.03 (+0.60), ICPT: 247.71 (+4.45)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 113.74 (+0.38), PFE: 34.36 (+0.50), GALT: 2.67 (+0.12), FGEN: 22.82 (+0.58), CELGZ: 2.15 (+0.14)
Intercept Pharmaceuticals: Serving Unmet Needs With Blockbuster Potential
DoconStocks - at Seeking Alpha - Tue Apr 28, 8:34AM CDT
GILD: 113.74 (+0.38), ICPT: 247.71 (+4.45)
Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
at The Street - Fri Apr 24, 8:12AM CDT
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
ICPT: 247.71 (+4.45)
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Apr 13, 4:18AM CDT
Summary
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 247.71 (+4.45)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 14.51 (-0.34), GILD: 113.74 (+0.38), CNAT: 4.83 (-0.09), ICPT: 247.71 (+4.45)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 247.71 (+4.45)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 247.71 (+4.45), TWTR: 34.91 (+0.55)
Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
at The Street - Fri Mar 27, 8:40AM CDT
The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
ICPT: 247.71 (+4.45)
Intercept up on Genfit's data-messaging presentation of NASH data
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:21PM CDT
ICPT: 247.71 (+4.45)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 99.53 (+1.13), GTXI: 1.37 (+0.01), ESPR: 90.01 (+1.32), ISIS: 53.50 (+0.42), PFE: 34.36 (+0.50), NEOT: 9.91 (+0.68), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin
at The Street - Fri Mar 13, 8:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
AMRN: 2.41 (+0.02), ICPT: 247.71 (+4.45), CUR: 1.69 (-0.01)
Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT
GLMD: 10.04 (+0.18), RPTP: 14.51 (-0.34), GILD: 113.74 (+0.38), LJPC: 31.43 (+0.94), CNAT: 4.83 (-0.09), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), GALT: 2.67 (+0.12), ICPT: 247.71 (+4.45), RGDO: 1.21 (unch)
Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.
at The Street - Wed Mar 11, 8:58AM CDT
It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.
ICPT: 247.71 (+4.45)
